鞘内布比卡因单药治疗慢性难治性局限性疼痛的病例系列
该回顾性病例系列纳入5例接受鞘内药物输注(IDD)布比卡因单药治疗的慢性局限性疼痛患者,IDD疗程从超过2年至超过12年不等。所有患者疼痛缓解≥50%并停用全身阿片类药物,提示布比卡因单药可能对局限性疼痛有效,但需更多研究确立其安全性与有效性。
要点
- 5例局限性慢性疼痛患者接受鞘内布比卡因单药治疗,均疼痛缓解≥50%。
- 所有患者均停用全身阿片类药物。
- 部分患者由阿片类药物联合布比卡因转换为布比卡因单药。
核心结论
- 鞘内布比卡因单药治疗可能对局限性疼痛患者有效,但需更多研究确立其安全性与有效性。
研究设计与样本
- 回顾性病例系列,纳入5例接受鞘内布比卡因单药治疗的慢性疼痛患者,收集人口学及疼痛与IDD特征。
主要发现
- 5例患者均为区域局限性疼痛,IDD疗程从超过2年至超过12年不等。
- 2例患者初始接受阿片类药物联合布比卡因,后转换为布比卡因单药。
- 3例患者在IDD前使用全身阿片类药物。
- 所有患者疼痛缓解≥50%并停用全身阿片类药物。
临床怎么用
- 对局限性慢性难治性疼痛患者,鞘内布比卡因单药可作为IDD的一种选择,但需个体化评估并监测安全性。
局限性
- 回顾性病例系列,样本量仅5例,证据等级有限。
- 鞘内布比卡因单药的安全性与有效性尚需更多研究确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Bupivacaine is an established agent in intrathecal drug delivery (IDD), often used in combination with opioids. The efficacy of intrathecal bupivacaine monotherapy has not been reported. METHODS: A retrospective case series review was undertaken examining patients with chronic pain who underwent device implants and were receiving intrathecal bupivacaine monotherapy. Data collection included patient demographics as well as pain and IDD characteristics. RESULTS: Five patients receiving intrathecal bupivacaine monotherapy were identified. All patients had regionally localized pain. Duration of IDD ranged from >2 to >12 years. Two of the patients had initially received a combination of an opioid with bupivacaine but were later transitioned to intrathecal bupivacaine monotherapy. Three of the patients were on systemic opioids prior to IDD. All patients experienced ≥50% pain relief and discontinued systemic opioids. CONCLUSION: IDD with bupivacaine monotherapy may be effective in patients with localized pain. However, more studies are needed to establish the safety and efficacy of intrathecal bupivacaine monotherapy.
引用
- Hayek SM, Alsalak C. Intrathecal bupivacaine monotherapy in patients with chronic refractory localized pain: a case series. Reg Anesth Pain Med. 2026. PMID: 42710945. doi:10.1136/rapm-2025-107562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。